Needham & Company Starts Clearside Biomedical (CLSD) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Cowen Starts Clearside Biomedical (CLSD) at Outperform
June 27, 2016 6:46 AM EDTCowen initiated coverage on Clearside Biomedical (NASDAQ: CLSD) with an Outperform rating.
For an analyst ratings summary and ratings history on Clearside Biomedical click here. For more ratings news on Clearside Biomedical click here.
Shares of Clearside Biomedical closed at $6.80 yesterday.
... MoreWedbush Starts Clearside Biomedical (CLSD) at Outperform, $28 PT
June 27, 2016 6:20 AM EDTWedbush initiates coverage on Clearside Biomedical (NASDAQ: CLSD) with a Outperform rating and a price target of $28.00.
Analyst Liana Moussatos commented, "We believe an investment in CLSD supports a dramatic improvement in injectable drug delivery for multiple eye diseases."
She added, "Clearside is a... More



